MA26610A1 - Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques - Google Patents

Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques

Info

Publication number: MA26610A1
Authority: MA; Morocco
Prior art keywords: racemic; isomers; salts; pharmaceutical compositions; therapeutic agents
Prior art date: 1998-02-27

Application number

MA25473A

Other languages

English (en)

Inventor

Marie Caroon Joan

Patrick Dillon Michael

New Harris Ralph Iii

Jeou Jen Lin Clara

Maag Hans

Bruce Repke David

Douglas Clark Robin

Surendra Hegde Sharathchandra

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-27

Filing date

1999-02-25

Publication date

2004-12-20

1999-02-25 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26610A1 publication Critical patent/MA26610A1/fr

Links

229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

MA25473A 1998-02-27 1999-02-25 Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques MA26610A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7611398P	1998-02-27	1998-02-27
US10909798P	1998-11-19	1998-11-19

Publications (1)

Publication Number	Publication Date
MA26610A1 true MA26610A1 (fr)	2004-12-20

Family

ID=26757679

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25473A MA26610A1 (fr)	1998-02-27	1999-02-25	Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques

Country Status (26)

Country	Link
US (1)	US6319920B1 (fr)
EP (1)	EP1058680B1 (fr)
JP (1)	JP3523198B2 (fr)
KR (1)	KR100384906B1 (fr)
CN (1)	CN1143848C (fr)
AR (1)	AR015523A1 (fr)
AT (1)	ATE400554T1 (fr)
AU (1)	AU753255B2 (fr)
BR (1)	BR9909253A (fr)
CA (1)	CA2321198C (fr)
CO (1)	CO4990939A1 (fr)
DE (1)	DE69939053D1 (fr)
ES (1)	ES2310032T3 (fr)
HR (1)	HRP20000544A2 (fr)
HU (1)	HUP0100760A3 (fr)
IL (1)	IL137936A0 (fr)
MA (1)	MA26610A1 (fr)
MY (1)	MY133445A (fr)
NO (1)	NO317106B1 (fr)
NZ (1)	NZ506317A (fr)
PE (1)	PE20000325A1 (fr)
PL (1)	PL194037B1 (fr)
RU (1)	RU2220138C2 (fr)
TR (1)	TR200002481T2 (fr)
WO (1)	WO1999043657A1 (fr)
YU (1)	YU53100A (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1012150A4 (fr) *	1997-05-19	2002-05-29	Sugen Inc	Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases
EP1289964B1 (fr) *	2000-05-25	2004-10-20	F. Hoffmann-La Roche Ag	1-aminoalkyle-lactames substitues et leur utilisation en tant qu'antagonistes de recepteur muscarinique
IL152701A0 (en)	2000-05-25	2003-06-24	Hoffmann La Roche	Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
ES2297029T3 (es)	2001-12-03	2008-05-01	F. Hoffmann-La Roche Ag	Derivados de aminotetralina como antagonistas de receptores muscarinicos.
DE60238709D1 (de)	2001-12-03	2011-02-03	Hoffmann La Roche	4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
CN100355419C (zh) *	2002-06-07	2007-12-19	安斯泰来制药有限公司	治疗膀胱过度活动的药物
AU2002345266B2 (en)	2002-07-08	2009-07-02	Ranbaxy Laboratories Limited	3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
CN100364990C (zh) *	2002-10-30	2008-01-30	施万制药	取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TWI295669B (en) *	2002-10-30	2008-04-11	Theravance Inc	Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (fr) *	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
AU2003301184A1 (en) *	2002-12-20	2004-07-22	Dynogen Pharmaceuticals Inc	METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
AU2004224322A1 (en) *	2003-03-21	2004-10-07	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP1618091A1 (fr)	2003-04-09	2006-01-25	Ranbaxy Laboratories, Ltd.	Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
JP2006522787A (ja)	2003-04-11	2006-10-05	ランバクシーラボラトリーズリミテッド	ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2005007645A1 (fr) *	2003-07-11	2005-01-27	Theravance, Inc.	Composes de 4-amino-1-benzylpiperidine substitues
FR2861073B1 (fr) *	2003-10-17	2006-01-06	Sanofi Synthelabo	Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US7214439B2 (en) *	2003-12-19	2007-05-08	Millennium Cell, Inc.	Triborohydride salts as hydrogen storage materials and preparation thereof
US8202891B2 (en) *	2007-04-24	2012-06-19	Theravance, Inc.	Quaternary ammonium compounds useful as muscarinic receptor antagonists
DE102007020492A1 (de) *	2007-04-30	2008-11-06	Grünenthal GmbH	Substituierte Sulfonamid-Derivate
EP3170807B1 (fr) *	2015-11-23	2019-12-11	Frau Pharma S.r.l.	Nouveau procédé de synthèse de la fenfluramine
SI25272A (sl)	2016-09-23	2018-03-30	Univerza V Ljubljani	Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
CN112824378A (zh) *	2019-11-20	2021-05-21	珠海润都制药股份有限公司	一种盐酸坦索罗辛的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0361791B1 (fr)	1988-09-26	1995-11-08	Smithkline Beecham Farmaceutici S.p.A.	Composés azacycliques, utiles commes médicaments
SU1829346A1 (ru) *	1991-04-01	1996-01-10	Институт Тонкой Органической Химии Им.А.Л.Мнджояна	ДИГИДРОХЛОРИДЫ N-[β-(1,2,5-ТРИМЕТИЛ-4-АРИЛПИПЕРИДИН-4-ИЛ)ЭТИЛ]-N-АЛКИЛ-N-(3,4-ДИМЕТОКСИБЕНЗИЛ)АМИНОВ, ЯВЛЯЮЩИЕСЯ ИНГИБИТОРАМИ КАЛЬЦИЙ-КАЛЬМОДУЛИНЗАВИСИМЫХ ПРОЦЕССОВ
MY110227A (en)	1991-08-12	1998-03-31	Ciba Geigy Ag	1-acylpiperindine compounds.
FR2681320B1 (fr)	1991-09-12	1994-01-14	Synthelabo	Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr)	1991-09-16	1993-12-17	Fabre Medicament Pierre	Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
DE69631058T2 (de)	1995-09-15	2004-06-03	Neurosearch A/S	Piperindinverbindungen als calcium-kanal-blocker
ATE205490T1 (de) *	1995-10-13	2001-09-15	Banyu Pharma Co Ltd	Substituierte heteroaromatische derivate

1999
- 1999-02-01 US US09/241,816 patent/US6319920B1/en not_active Expired - Fee Related
- 1999-02-19 CN CNB998045322A patent/CN1143848C/zh not_active Expired - Fee Related
- 1999-02-19 HR HR20000544A patent/HRP20000544A2/hr not_active Application Discontinuation
- 1999-02-19 DE DE69939053T patent/DE69939053D1/de not_active Expired - Lifetime
- 1999-02-19 TR TR2000/02481T patent/TR200002481T2/xx unknown
- 1999-02-19 YU YU53100A patent/YU53100A/sh unknown
- 1999-02-19 AU AU28353/99A patent/AU753255B2/en not_active Ceased
- 1999-02-19 NZ NZ506317A patent/NZ506317A/en unknown
- 1999-02-19 KR KR10-2000-7009431A patent/KR100384906B1/ko not_active Expired - Fee Related
- 1999-02-19 CA CA002321198A patent/CA2321198C/fr not_active Expired - Fee Related
- 1999-02-19 PL PL99342692A patent/PL194037B1/pl unknown
- 1999-02-19 AT AT99908933T patent/ATE400554T1/de not_active IP Right Cessation
- 1999-02-19 RU RU2000124676/04A patent/RU2220138C2/ru not_active IP Right Cessation
- 1999-02-19 BR BR9909253-0A patent/BR9909253A/pt not_active Application Discontinuation
- 1999-02-19 HU HU0100760A patent/HUP0100760A3/hu unknown
- 1999-02-19 IL IL13793699A patent/IL137936A0/xx unknown
- 1999-02-19 EP EP99908933A patent/EP1058680B1/fr not_active Expired - Lifetime
- 1999-02-19 ES ES99908933T patent/ES2310032T3/es not_active Expired - Lifetime
- 1999-02-19 JP JP2000533415A patent/JP3523198B2/ja not_active Expired - Fee Related
- 1999-02-19 WO PCT/EP1999/001102 patent/WO1999043657A1/fr not_active Ceased
- 1999-02-23 PE PE1999000155A patent/PE20000325A1/es not_active Application Discontinuation
- 1999-02-24 CO CO99011501A patent/CO4990939A1/es unknown
- 1999-02-24 AR ARP990100772A patent/AR015523A1/es not_active Application Discontinuation
- 1999-02-25 MY MYPI99000700A patent/MY133445A/en unknown
- 1999-02-25 MA MA25473A patent/MA26610A1/fr unknown
2000
- 2000-08-25 NO NO20004261A patent/NO317106B1/no unknown

Also Published As

Publication number	Publication date
PL194037B1 (pl)	2007-04-30
KR20010041321A (ko)	2001-05-15
HUP0100760A3 (en)	2002-12-28
MY133445A (en)	2007-11-30
HUP0100760A2 (hu)	2001-08-28
PE20000325A1 (es)	2000-05-08
PL342692A1 (en)	2001-07-02
CA2321198C (fr)	2009-11-17
ES2310032T3 (es)	2008-12-16
AR015523A1 (es)	2001-05-02
EP1058680B1 (fr)	2008-07-09
AU2835399A (en)	1999-09-15
IL137936A0 (en)	2001-10-31
ATE400554T1 (de)	2008-07-15
YU53100A (sh)	2003-04-30
CA2321198A1 (fr)	1999-09-02
BR9909253A (pt)	2000-11-28
NO20004261D0 (no)	2000-08-25
NO317106B1 (no)	2004-08-09
JP3523198B2 (ja)	2004-04-26
EP1058680A1 (fr)	2000-12-13
KR100384906B1 (ko)	2003-05-23
TR200002481T2 (tr)	2000-11-21
CN1295563A (zh)	2001-05-16
DE69939053D1 (de)	2008-08-21
CN1143848C (zh)	2004-03-31
JP2002504543A (ja)	2002-02-12
HK1036623A1 (en)	2002-01-11
NO20004261L (no)	2000-08-25
AU753255B2 (en)	2002-10-10
NZ506317A (en)	2003-08-29
RU2220138C2 (ru)	2003-12-27
CO4990939A1 (es)	2000-12-26
US6319920B1 (en)	2001-11-20
WO1999043657A1 (fr)	1999-09-02
HRP20000544A2 (en)	2001-02-28

Publication	Publication Date	Title
MA26610A1 (fr)	2004-12-20	Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques
MA26415A1 (fr)	2004-12-20	Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
FR2780728B1 (fr)	2001-02-16	Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2789079B3 (fr)	2001-03-02	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
MA26471A1 (fr)	2004-12-20	Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26571A1 (fr)	2004-12-20	Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN97144A1 (fr)	2005-03-15	Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26653A1 (fr)	2004-12-20	Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2785902B1 (fr)	2003-09-26	4-aroylpiperidines antagonistes du recepteur du ccr-3, compositions pharmaceutiques les contenant, procede pour les utiliser et les preparer
MA26516A1 (fr)	2004-12-20	Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
MA26620A1 (fr)	2004-12-20	Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99126A1 (fr)	2005-11-10	Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99142A1 (fr)	2005-11-10	Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
TNSN98083A1 (fr)	2005-03-15	Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98066A1 (fr)	2005-03-15	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr)	2004-12-20	Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
HK1047036A1 (zh)	2003-02-07	用於治疗偏头痛的选择性iglur5，受体拮抗剂
FR2687676B1 (fr)	1994-07-08	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
TNSN99056A1 (fr)	2005-11-10	Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00106A1 (fr)	2005-11-10	Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation